Peroxisome proliferator-activated receptor gamma (PPAR-gamma): a novel therapeutic target for asthma?

Not Applicable

Completed

• Conditions: Asthma; Respiratory

• Registration Number: ISRCTN80109258
• Lead Sponsor: niversity of Nottingham (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-04-16
• Last Update Posted: 8 May 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Aged 18 - 75 years, of either sex, with a clinical diagnosis of asthma
2. Forced expiratory volume in one second (FEV1) greater than or equal to 60% predicted and an increase in forced expiratory volume in one second (FEV1) of greater than 12% following inhaled salbutamol 400 µg or peak flow variability greater than 12% during run in
3. Permitted medication, 0 - 800 µg inhaled beclomethasone diproprionate or equivalent and a short acting beta-2-agonist as required

Exclusion Criteria

1. Inability to produce a sputum sample on induction
2. Currently smoking
3. Greater than 10 pack years smoking history
4. Treatment with leukotriene antagonists
5. Long-acting beta agonists or theophylline
6. Liver or cardiovascular disease
7. Oral steroid treatment or exacerbation within 6 weeks
8. Females who are pregnant, lactating or not using adequate contraception
9. Any contra-indication to pioglitazone (hypersensitivity to pioglitazone, cardiac failure, history of cardiac failure, hepatic impairment, diabetic ketoacidosis)
10. Oral or insulin treatment for diabetes
11. Treatment with gemfibrozol or rifampicin

Study & Design

• Study Type: Interventional
• Study Design: Not specified